Passini N, Larigan J D, Genovese S, Appella E, Sinigaglia F, Rogge L
Roche Milano Ricerche, Italy.
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9412-6. doi: 10.1073/pnas.92.20.9412.
Major targets for autoantibodies associated with the development of insulin-dependent diabetes mellitus (IDDM) include tryptic fragments with a molecular mass of 37 kDa and/or 40 kDa of a pancreatic islet cell antigen of unknown identity. The assay identifying autoantibodies against the 37/40-kDa antigen in human sera is based on the immunoprecipitation of 35S-labeled rat insulinoma cell proteins with sera from IDDM patients, followed by limited trypsin digestion of the immunoprecipitated material. To identify cDNA clones coding for the 37/40-kDa antigen, we have screened a cDNA expression library from rat insulinoma cells with a serum from an IDDM patient that precipitated the 37/40-kDa antigen in our assay. Among the cDNA products that reacted with the IDDM serum, we identified one cDNA clone whose open reading frame encodes a protein with a predicted mass of 105 kDa that we termed "ICA105" for 105-kDa islet cell antibody. The deduced amino acid sequence has high homology to a recently cloned putative tyrosine phosphatase IA-2 from human and mouse cDNA libraries. Translation of the cDNA in vitro results in a polypeptide with the expected molecular mass of 105 kDa. The evidence that ICA105 is indeed the precursor of the 37/40-kDa tryptic fragments is based on the following three results: (i) Sera from IDDM patients containing autoantibodies to the 37/40-kDa antigen precipitate the in vitro translated polypeptide, whereas sera from healthy subjects as well as sera from IDDM patients not reactive with the 37/40-kDa antigen do not precipitate the cDNA product. (ii) Immunoprecipitation of the in vitro translated protein with sera containing autoantibodies to the 37/40-kDa antigen followed by limited trypsin digestion of the precipitated proteins results in a 40-kDa polypeptide. (iii) The protein derived from our cDNA but not from an unrelated control cDNA clone can block immunoprecipitation of the 37/40-kDa antigen from a labeled rat insulinoma cell extract. The availability of the cloned 37/40-kDa antigen should facilitate the identification of individuals at risk of IDDM with increased accuracy. Furthermore, the identification of the 37/40-kDa antigen as the putative tyrosine phosphatase IA-2 is of relevance in elucidating the role of this antigen in the development of IDDM.
与胰岛素依赖型糖尿病(IDDM)发病相关的自身抗体主要靶标包括一种身份不明的胰岛细胞抗原的分子量为37 kDa和/或40 kDa的胰蛋白酶片段。鉴定人血清中针对37/40 kDa抗原的自身抗体的检测方法是基于用IDDM患者的血清对35S标记的大鼠胰岛素瘤细胞蛋白进行免疫沉淀,然后对免疫沉淀物质进行有限的胰蛋白酶消化。为了鉴定编码37/40 kDa抗原的cDNA克隆,我们用在我们的检测中沉淀37/40 kDa抗原的一名IDDM患者的血清筛选了大鼠胰岛素瘤细胞的cDNA表达文库。在与IDDM血清反应的cDNA产物中,我们鉴定出一个cDNA克隆,其开放阅读框编码一种预测分子量为105 kDa的蛋白质,我们将其称为“ICA105”,即105 kDa胰岛细胞抗体。推导的氨基酸序列与最近从人和小鼠cDNA文库中克隆的假定酪氨酸磷酸酶IA-2具有高度同源性。该cDNA的体外翻译产生一种预期分子量为105 kDa的多肽。ICA105确实是37/40 kDa胰蛋白酶片段前体的证据基于以下三个结果:(i)含有针对37/40 kDa抗原的自身抗体的IDDM患者血清沉淀体外翻译的多肽,而健康受试者的血清以及与37/40 kDa抗原无反应的IDDM患者血清不沉淀cDNA产物。(ii)用含有针对37/40 kDa抗原的自身抗体的血清对体外翻译的蛋白质进行免疫沉淀,然后对沉淀的蛋白质进行有限的胰蛋白酶消化,产生一种40 kDa的多肽。(iii)源自我们的cDNA而非无关对照cDNA克隆的蛋白质可以阻断从标记的大鼠胰岛素瘤细胞提取物中对37/40 kDa抗原的免疫沉淀。克隆的37/40 kDa抗原的可得性应有助于更准确地识别有IDDM风险的个体。此外,将37/40 kDa抗原鉴定为假定的酪氨酸磷酸酶IA-2对于阐明该抗原在IDDM发病中的作用具有重要意义。